HIV, hepatitis C, and hepatitis B infections and associated risk behavior in injection drug users, Kabul, Afghanistan

Emerging Infectious Diseases

Volumn 13, Issue 9, 2007, Pages 1327-1331

  Todd, Catherine S ^a   Abed, Abdullah M S ^b   Strathdee, Steffanie A ^a   Scott, Paul T ^c   Botros, Boulos A ^d   Safi, Naqibullah ^b   Earhart, Kenneth C ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Ministry of Public Health   (Afghanistan)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d US Naval Medical Research Unit No 3 Egypt   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY;

ADULT; AFGHANISTAN; ANTIBODY DETECTION; ANTIGEN DETECTION; ARTICLE; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; PREVALENCE; PROSTITUTION; QUESTIONNAIRE; VIRUS DETECTION;

EID: 34848914034     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1309.070036     Document Type: Article

References (26)

1. United Nations Development Program. HIV/AIDS in Central and Eastern Europe and the Commonwealth of Independent States: reversing the epidemic, facts and policy options. Bratislava (Slovak Republic): Renesans; 2004. p. 11-24.
2. International Crisis Group. Central Asia: drugs and conflict. Asia report No. 25. Brussels: the Group; 2001.
3. The Joint United Nations Program on HIV/AIDS. 2006 report on the global AIDS epidemic. Geneva: the Program; 2006.
4. Beyrer C. Human immunodeficiency virus (HIV) infection rates and drug trafficking: fearful symmetries. Bulletin on Narcotics. 2002;54:103-16.
5. Stachowiak JA, Tishkova FK, Strathdee SA, Stibich MA, Latypov A, Mogilnii V, et al. Marked ethnic differences in HIV prevalence and risk behaviors among injection drug users in Dushanbe, Tajikistan, 2004. Drug Alcohol Depend. 2006;82(Suppl 1):S7-14.
6. Sanchez JL, Todd CS, Bautista CT, Botros BA, Khakimov MM, Giyasova GM, et al. High HIV prevalence and risk factors among injecting drug users in Tashkent, Uzbekistan, 2003-04. Drug Alcohol Depend. 2006;82(Suppl 1):S15-22.
7. Ittig A. Urban development in Kabul: an overview of challenges and strategies. [cited 2006 May 27]. Available from http://www.institute-for-afghan- studies.org/contributions/projects/dr-ittig/urbandev.htm
8. IRIN News Organization. UNHCR to assist 150,000 Afghan Refugees in 2006. March 2, 2006. [cited 2006 Jul 13]. Available from http://www.irinnews.org/ report.asp?reportid=51991&selectregion=asia&selectcountry=iran
9. United Nations Office on Drugs and Crime. 2006 world drug report. Vienna: the Office; 2006.
10. United Nations Office on Drugs and Crime. Afghanistan drug use survey 2005. Kabul (Afghanistan): the Office; 2005.
11. United Nations Office on Drugs and Crime. Community drug profile #5: an assessment of problem drug use in Kabul city. Kabul (Afghanistan): the Office; 2003.
12. Zafar T, Brahmbhatt H, Imam G, ul Hassan S, Strathdee SA. HIV knowledge and risk behaviours among Pakistani and Afghani drug users in Quetta, Pakistan. J Acquir Immune Defic Syndr. 2003;32:394-8.
13. Hankins CA, Friedman SR, Zafar T, Strathdee SA. Transmission and prevention of HIV and sexually transmitted infections in war settings: implications for current and future armed conflicts. AIDS. 2002;16:2245-52.
14. Todd CS, Safi N, Strathdee SA. Drug use and harm reduction in Afghanistan. Harm Reduct J. 2005;2:13.
15. Integrated Regional Information Network News Afghanistan. Increase in people living with HIV/AIDS. October 11, 2005. [cited 2006 Jun 7]. Available from http://www.irinnews.org/report.asp?reportid=49483
16. World Health Organization. Hepatitis B surface antigen assays: operational characteristics. Phase 1. Geneva: the Organization; 2001.
17. Standard Diagnostics. Rapid test: hepatitis information sheet. [cited 2007 Apr 17]. Available from http://www.standardia.com/eng_product/ rapid_hepatitls.asp
18. Zamani S, Kihara M, Gouya MM, Vazirian M, Ono-Kihara M, Razzaghi EM, et al. Prevalence of and factors associated with HIV-1 infection among drug users visiting treatment centers in Tehran, Iran. AIDS. 2005;19:709-16.
19. Choopanya K, Des Jarlais DC, Vanichseni S, Kitayayporn D, Mock PA, Raktham S, et al. Incarceration and risk for HIV infection among injection drug users in Bangkok. J Acquir Immune Defic Syndr. 2002;29:86-94.
20. Zamani S, Kihara M, Gouya MM, Vazirian M, Nassirimanesh B, Ono-Kihara M, et al. High prevalence of HIV infection associated with incarceration among community-based injecting drug users in Tehran, Iran. J Acquir Immune Defic Syndr. 2006;42:342-6.
21. Mast E, Mahoney F, Kane MA, Margolis HS. Hepatitis B vaccine. In: Plotkin SA, Orenstein WA, Offitt PA, editors. Vaccines, 4th ed. Philadelphia: W.B. Saunders Company; 2004. p. 299-338.
22. Global Fund. Building Afghanistan's capacity to address HIV, TB, and malaria. [cited 2006 May 29]. Available from http://www.theglobalfund.org/ programs/grantdetails.aspx?countryid=afg&compid=113&grantid=311
23. Khan AJ, Luby SP, Fikree F, Karim A, Obaid S, Dellawala S, et al. Unsafe injections and the transmission of hepatitis B and C in a periurban community in Pakistan. Bull World Health Organ. 2000;78:956-63.
24. Remis RS, Bruneau J, Hankins CA. Enough sterile syringes to prevent HIV transmission among injection drug users in Montreal? J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(Suppl 1):S57-9.
25. Strathdee SA, van Ameijden EJ, Mesquita F, Wodak A, Rana S, Viahov D. Can HIV epidemics among injection drug users be prevented? AIDS. 1998;12 Suppl A:S71-9.
26. Des Jarlais DC, Hagan H, Friedman SR, Friedmann P, Goldberg P, Frischer M, et al. Maintaining low HIV seroprevalence in populations of injecting drug users. JAMA. 1995;274:1226-31.